Alzheimer disease (AD) may develop after the onset of type 2 diabetes mellitus (T2DM), and the risk of AD may depend on the antidiabetic drug administered. We compared the risk of AD among 66 085 patients (≥ 65 years) with T2DM (1250 having concomitant AD) who had been administered antidiabetic drug monotherapy for T2DM who had voluntarily reported themselves in the Food and Drug Administration Adverse Event Reporting System. The risk of AD from the use of different antidiabetic drug monotherapies compared to that of metformin monotherapy was assessed by logistic regression. Rosiglitazone (adjusted reporting odds ratio [aROR] = 0.11; 95% confidence interval [CI]: 0.07-0.17; P < .001), exenatide (aROR = 0.22; 95% CI: 0.11-0.37; P < .001), liraglutide (aROR = 0.36; 95% CI: 0.19-0.62; P < .001), dulaglutide (aROR = 0.39; 95% CI: 0.17-0.77; P = .014), and sitagliptin (aROR = 0.75; 95% CI: 0.60-0.93; P = .011) were found to have a significantly lower associated risk of AD than that of metformin. Therefore, the administration of glucagon-like peptide 1 receptor agonists and rosiglitazone may reduce the risk of AD in patients with T2DM.

中文翻译：

---

使用FAERS在2型DM患者中使用抗糖尿病药物治疗阿尔茨海默氏病的风险。

阿尔茨海默病（AD）可能在2型糖尿病（T2DM）发作后发展，并且AD的风险可能取决于所服用的抗糖尿病药物。我们比较了66085例（≥65岁）患有T2DM（1250例同时有AD）的T2DM接受抗糖尿病药物单药治疗并自愿在食品和药物管理局不良事件报告系统中报告自己的患者的AD风险。通过Logistic回归评估与二甲双胍单一疗法相比，使用不同的抗糖尿病药物单一疗法引起的AD风险。罗格列酮（调整后的报告比值比[aROR] = 0.11; 95％置信区间[CI]：0.07-0.17; P <.001），艾塞那肽（aROR = 0.22; 95％CI：0.11-0.37; P <.001），利拉鲁肽（aROR = 0.36; 95％CI：0.19-0.62; P <.001），度拉鲁肽（aROR = 0.39; 95％CI：0.17-0.77; P = .014）和西他列汀（aROR = 0.75； 95％CI：0.60-0.93； P = .011）与二甲双胍相比，其相关的AD风险显着降低。因此，给予胰高血糖素样肽1受体激动剂和罗格列酮可降低T2DM患者的AD风险。